Takeda Pharmaceutical CO LTD Form 4 insider transactions

Natalie Anne Marie Furney, Global General Counsel at Takeda Pharmaceutical Co Ltd, received an award of 43,886 American Depositary Shares represented by Restricted Stock Units (RSUs).

Rhonda Pacheco, President of Takeda's U.S. Business Unit, received an award of 50,156 Restricted Stock Units (RSUs) on July 1, 2026.

Marcello Agosti, Head of Strategy & Portfolio Development at Takeda Pharmaceutical, received an award of 27,586 Restricted Stock Units (RSUs) on July 1, 2026.

Gabriele Ricci, Chief Data & Tech Officer at Takeda Pharmaceutical, acquired 37,616 American Depositary Shares through an RSU award.

Elaine M. Shannon, President of Global Supply & Quality at Takeda Pharmaceutical Co Ltd, reported an award of 30,094 Restricted Stock Units (RSUs).

Takeda Pharmaceutical Co Ltd executive Lauren Rusckowski Duprey reports an award of 45,140 Restricted Stock Units (RSUs) vesting over three years.

Teresa Marie Bitetti, President of OBU at Takeda Pharmaceutical Co Ltd, acquired 43,886 American Depositary Shares through an RSU award.

Takeda Pharmaceutical Co. Ltd. executive Julie So-Young Kim reports transactions involving American Depositary Shares and Ordinary Shares, including awards of restricted stock units.

Andrew Stewart Plump, President of R&D at Takeda Pharmaceutical, reported transactions involving American Depositary Shares and restricted stock units.

Takeda Pharmaceutical Co. Ltd. CEO Christophe Weber was granted performance-based restricted stock units (RSUs) for ordinary shares and American Depositary Shares on April 27, 2026.

Milano Furuta, Chief Financial Officer and Director at Takeda Pharmaceutical Co Ltd, reported transactions involving ordinary shares and restricted stock units.

Andrew Plump, President of R&D at Takeda Pharmaceutical, received a significant award of restricted stock units (RSUs) based on performance metrics.

Gabriele Ricci, Chief Data & Tech Officer at Takeda Pharmaceutical, was awarded restricted stock units (RSUs) based on performance metrics, with vesting scheduled through 2028.

Teresa Bitetti, President of OBU at Takeda Pharmaceutical Co Ltd, has been granted an award of restricted stock units (RSUs) based on performance metrics.

Takeda Pharmaceutical Co. Ltd. reports that Chief Transformation Officer Lauren Duprey Rusckowski was awarded restricted stock units (RSUs) based on performance metrics.

Takeda Pharmaceutical Co. Ltd. reports on changes in beneficial ownership for executive Julie So-Young Kim, detailing RSU awards based on performance metrics.

Giles Platford, President of IBU at Takeda Pharmaceutical, received an award of restricted stock units (RSUs) based on performance metrics, with vesting scheduled through 2028.

Takeda Pharmaceutical Co Ltd converted 1,250 shares of Ovid Therapeutics Inc. Series A Preferred Stock into 1.25 million common shares and reported a net beneficial ownership of 7 million common shares after a disposition.

Takeda Pharmaceutical Company Limited and its subsidiary Takeda Vaccines, Inc. have sold their entire 6,724,000 shares of HilleVax, Inc. common stock for $1.95 per share as part of a tender offer by XOMA Royalty Corporation.